ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the molecular targets and physiological mechanisms underlying the therapeutic efficacy of Jianpi Qingre Lishi prescription (, JQLP) in the treatment of non-alcoholic steatohepatitis (NASH).
methodsThis study used 120 Sprague-Dawley rats to establish six groups at random (
resultsCompared to the BC group, the model group showed no significant changes in fasting blood glucose (FBG), which was substantially reduced after both M-JQLP and H-JQLP treatments. MCD diet induced a series of pathological alterations, such as extensive vacuole-like steatosis, disorganized hepatic plates, and significant inflammatory cell infiltration in liver tissues, which were dose-dependently weakened by JQLP intervention. Rats fed with MCD diet demonstrated increase in total cholesterol, triglyceride, low-density lipoprotein cholesterol, alanine aminotransferase and aspartate aminotransferase activities, but decrease in high-density lipoprotein cholesterol. JQLP treatment effectively normalized these parameters in a dose-dependent manner. Furthermore, rats with MCD diet were detected with largely secreted tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6); while JQLP intervention decreased TNF-α and IL-6 secretion, but enhanced IL-4 content. Additionally, miR-27 upregulation and PPARγ downregulation were induced in liver tissues of rats with MCD diet, which were counteracted by JQLP treatment.
conclusionsJQLP can ameliorate NASH progression, potentially through the regulation of miR-27/ PPARγ axis. JQLP may be a promising therapeutic candidate worthy of further clinical investigation for NASH treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.